Catheter Related Bloodstream Infections Market to Expand Through 2034, Backed by 674,000+ Annual Cases Across 7MM and Robust Late-Stage Pipeline Momentum, analyses DelveInsight

DelveInsight's "Catheter Related Bloodstream Infections Market Insights, Epidemiology, and Market Forecast-2034" report provides a comprehensive evaluation of Catheter Related Bloodstream Infections (CRBSI), covering historical and projected epidemiological data along with detailed market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

For a detailed assessment of the Catheter Related Bloodstream Infections market outlook, drug adoption patterns, treatment landscape, and epidemiological forecasts, visit: Catheter Related Bloodstream Infections Market Forecast - hhttps://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Catheter Related Bloodstream Infections Market Report:
• The Catheter Related Bloodstream Infections market is projected to expand at a robust CAGR throughout the forecast period (2020-2034).
• In November 2024, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a biopharmaceutical company specializing in first-in-class critical care products, announced a productive in-person Type C meeting with the U.S. FDA. This meeting followed the successful completion of its pivotal Phase III trial for Mino-Lok®, an innovative catheter lock solution designed to salvage central venous catheters in patients suffering from central line-associated bloodstream infections (CLABSI) or CRBSI. Discussions primarily centered on the FDA's queries regarding clinical data and the regulatory pathway for submission.
• In May 2024, Citius Pharmaceuticals reported encouraging topline data from its Phase III study of Mino-Lok. The trial met its primary endpoint, demonstrating statistically significant improvement in time to catheter failure compared with clinician-directed anti-infective lock solutions in the control arm.
• According to DelveInsight estimates, the total incident CRBSI population across the 7MM was approximately 674,000 cases in 2020 and is expected to rise during the forecast timeline.
• The United States recorded the highest number of CRBSI cases, with nearly 331,000 incidents in 2020.
• Epidemiological analysis in the US indicates that Gram-positive bacterial infections account for a larger proportion of cases compared to Gram-negative bacteria, while fungal infections caused by Candida species represent a relatively small share.
• Within EU4 and the UK, Germany reported the highest number of incident cases, exceeding 62,000 in 2020, whereas Spain recorded the lowest, with approximately 17,000 cases.
• Leading companies active in the Catheter Related Bloodstream Infections space include CorMedix, Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix, Inc., TauroPhar GmbH, Geistlich Pharma, Citius Pharmaceuticals, AstraZeneca, Merck & Co., Inc., and others.
• Prominent therapies in the market include DEFENCATH, Mino-Lok, Neutrolin, Daptomycin, Linezolid, among others.
• Gender-based epidemiological analysis suggests that CRBSI incidence is notably higher in non-ICU settings.
• The market is poised for substantial growth driven by increasing infection rates and rising awareness. Additionally, the introduction of late-stage pipeline candidates is expected to significantly reshape the competitive and commercial landscape.

Catheter Related Bloodstream Infections Overview
Catheter-related bloodstream infection (CRBSI) refers to bacteremia originating from an intravenous catheter. It remains one of the most common, life-threatening, and expensive complications associated with central venous catheter use, and is a leading cause of hospital-acquired (nosocomial) bloodstream infections.

Access a free sample of the Catheter Related Bloodstream Infections Market Report here:
https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Catheter Related Bloodstream Infections Epidemiology
Across the seven major markets (7MM), the United States reported the largest number of incident cases of catheter-related bloodstream infections in 2023.

Data analysis indicates that, in the US, infections caused by Gram-positive bacteria are more prevalent than those caused by Gram-negative organisms, while cases linked to Candida species (fungal infections) represent only a small proportion. Within the Gram-positive category, methicillin-susceptible Staphylococcus aureus accounts for the largest share of patients.

Among the EU4 countries and the United Kingdom, Germany recorded the highest number of incident CRBSI cases in 2023, whereas Spain reported the lowest.

Epidemiology Segmentation (2020-2034, 7MM):
• Overall prevalence of Catheter Related Bloodstream Infections
• Severity-based prevalent cases
• Gender-specific prevalence
• Diagnosed episodic and chronic CRBSI cases

Download the report to explore factors influencing epidemiology trends: https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Catheter Related Bloodstream Infections Drug Uptake and Pipeline Development
MINO-LOK: Citius Pharmaceuticals
MINO-LOK is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections and central line-associated bloodstream infections (CLABSIs), MINO-LOK is the only therapy under investigation to salvage infected central venous catheterization. In a Phase IIb trial, MINO-LOK demonstrated a 100% efficacy rate in salvaging colonized central venous catheterization; MINO-LOK had no significant adverse events compared to an 18% serious adverse event rate when infected central venous catheterization was removed and replaced. A multicenter Phase III pivotal superiority trial is currently underway. MINO-LOK contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in central venous catheterization and salvage the indwelling catheter. MINO-LOK is used in two-hour locking cycles, allowing central venous catheterization to be used for its intended purposes for the remaining 22 hours each day.

Key Catheter Related Bloodstream Infections Therapies and Companies
• DEFENCATH - CorMedix
• Mino-Lok - Citius Pharmaceuticals
• Neutrolin - CorMedix
• Daptomycin - Cubist Pharma
• Linezolid - Pfizer

Explore therapies expected to capture significant market share: https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Catheter Related Bloodstream Infections Market Outlook
When a catheter-related bloodstream infection (CRBSI) is suspected, clinical guidelines primarily recommend immediate catheter removal. If fever persists after removal, patients are typically started on antibiotic and antifungal therapy, often on an empirical basis.

Commonly used off-label antibacterial agents for CRBSI management include daptomycin, vancomycin, cefazolin, ampicillin, ciprofloxacin, amikacin, and teicoplanin. For fungal infections, antifungals such as fluconazole and amphotericin B are also prescribed off-label. Although the treatment landscape is expected to evolve, progress is likely to be gradual, as only one company currently has a novel therapy in late-stage clinical development.

Leading players, including Citius Pharmaceuticals, are advancing key pipeline candidates across various stages of development, aiming to introduce improved treatment options for CRBSI.

DEFENCATH, which has received US approval for CRBSI, holds strong commercial potential, particularly with anticipated regulatory approvals in Europe and Japan. Market expansion during the forecast period is expected to be supported by rising disease prevalence, greater patient awareness, and updated diagnostic and treatment guidelines.
Among the seven major markets (7MM), the United States represented the largest share of the CRBSI market in 2023.

Catheter Related Bloodstream Infections Market Drivers
• Increasing incidence of hospital-acquired infections (HAIs) and widespread use of central venous catheters in oncology and critical care settings
• Heightened awareness of infection control protocols and antimicrobial stewardship programs
• Innovations in antimicrobial-coated and impregnated catheter technologies
• Growing need for advanced diagnostics and rapid infection detection tools
• Expansion of healthcare facilities and ICU capacities worldwide
• Strong R&D investments and product innovation by leading industry players

Catheter Related Bloodstream Infections Market Challenges
• High costs associated with advanced antimicrobial technologies
• Limited protocol adherence and awareness in resource-constrained regions
• Rising antimicrobial resistance impacting treatment effectiveness
• Stringent regulatory requirements for approval of novel catheter technologies
• Variability in reimbursement frameworks across healthcare systems
• Clinical risks and adverse events linked to catheter usage

Scope of the Catheter Related Bloodstream Infections Market Report
• Study Timeline: 2020-2034
• Geographical Coverage: 7MM (United States, EU5, and Japan)
• Major Companies: CorMedix, Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix, Inc., TauroPhar GmbH, Geistlich Pharma, Citius Pharmaceuticals, AstraZeneca, Merck & Co., Inc., and others
• Key Therapies: DEFENCATH, Mino-Lok, Neutrolin, Daptomycin, Linezolid, among others
• Therapeutic Evaluation: Marketed and emerging therapies
• Market Dynamics: Drivers and barriers
• Competitive Intelligence: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, and entry strategies
• Unmet Needs, KOL Insights, Analyst Perspectives, and Market Access & Reimbursement Analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.